BALTIMORE — The standard Medicare Part B premium will rise by $21.60 a month to $170.10 in 2022, a sharp increase that will absorb a meaningful share of next year’s Social Security cost-of-living adjustment and reflects both rising medical spending and uncertainty over the potential cost of the newly approved Alzheimer’s drug Aduhelm.

The Centers for Medicare & Medicaid Services announced Friday that the standard premium will increase from $148.50 in 2021, while the annual Part B deductible will rise by $30 to $233. In its detailed fact sheet, CMS said the increase reflects higher prices and utilization across the health system, congressional limits that held down the 2021 increase, and additional contingency reserves associated with uncertain use of Aduhelm.

A 5.9% Social Security increase meets a larger Medicare deduction

The increase comes just as retirees are preparing for the largest Social Security cost-of-living adjustment in decades. The Social Security Administration announced in October that benefits for roughly 70 million Americans will rise 5.9% in 2022. The agency’s announcement said the adjustment will begin with January benefits for more than 64 million Social Security recipients.

For beneficiaries who have their Medicare premium deducted directly from Social Security, the two changes arrive together. CMS said a retired worker receiving $1,565 a month in Social Security in 2021 would still see a net increase after the higher Part B premium is deducted, but the Medicare increase reduces the amount of the COLA that can be used for other household expenses.

The arithmetic is especially important because older Americans face the same inflation pressures as other households, including higher food, energy and housing costs. Part B premiums are not optional for most beneficiaries who want outpatient medical coverage, so the increase functions as a fixed monthly claim on retirement income.

Aduhelm creates an unusually large unknown

CMS explicitly identified Aduhelm as one reason for holding additional reserves. The Food and Drug Administration granted accelerated approval to aducanumab in June based on its effect on amyloid plaque, a surrogate endpoint judged reasonably likely to predict clinical benefit. An FDA decision memorandum records the agency’s rationale and the internal disagreement surrounding the application.

The drug’s list price of about $56,000 a year has made Medicare coverage unusually consequential because Alzheimer’s disease disproportionately affects older adults. If even a modest share of eligible Medicare beneficiaries receives a physician-administered drug at that price, Part B spending could rise substantially. Yet CMS has not decided whether a national coverage policy will pay for the drug broadly, narrowly or only under specified evidence requirements.

In July, CMS opened a formal coverage review covering aducanumab and future monoclonal antibodies targeting amyloid. The agency said the process could result in national coverage, coverage with evidence development, noncoverage or continued reliance on local Medicare contractor decisions. A proposed decision is expected within six months of the review’s opening.

The scientific debate complicates the financial forecast

The uncertainty is not simply administrative. Aduhelm’s approval has generated an unusually public dispute over whether plaque reduction is a sufficiently reliable substitute for demonstrated cognitive benefit. A September JAMA Neurology analysis questioned whether amyloid load should be treated as a validated surrogate endpoint for clinical outcomes in Alzheimer’s trials.

FDA officials have defended the accelerated-approval pathway, arguing that the evidence establishes an effect on amyloid and that the drug addresses a severe disease with few treatment options. Their July explanation described the rationale for approving aducanumab despite conflicting clinical trial results and requiring a post-approval study to verify clinical benefit.

That scientific uncertainty feeds directly into Medicare’s actuarial problem. The program must set premiums before it knows the ultimate national coverage policy, the number of physicians prepared to administer the drug, the share of patients who meet prescribing criteria or the speed of uptake. If CMS sets the premium too low and spending accelerates, Part B reserves bear the risk. If it sets the premium too high and use remains limited, beneficiaries have paid more than immediate claims experience would require.

Part B financing pushes uncertainty onto current premiums

By law, beneficiary premiums finance about one-quarter of projected Part B costs for the aged population, with general federal revenues covering most of the remainder. CMS therefore has to make forward-looking estimates about physician services, outpatient care, drugs and other covered spending before the year begins.

The agency also noted that Congress limited the 2021 premium increase during the pandemic, effectively spreading part of that adjustment into later years. That policy interacts with ordinary medical cost growth and the Aduhelm reserve, producing a larger increase for 2022 than beneficiaries might have expected from any single factor.

The premium announcement therefore captures several pressures converging at once: recovery from pandemic-era utilization changes, rising health-care prices, statutory financing rules and the arrival of an exceptionally expensive drug whose coverage remains unsettled.

For Medicare beneficiaries, the immediate number is simple: $170.10 a month for the standard Part B premium next year, plus a $233 deductible. Behind that number is a much larger policy question — how Medicare should finance new high-cost therapies when evidence, coverage and patient demand are still evolving.